Comparing the current results to its competitors, Bausch Health Companies Inc reported Revenue increase in the 1 quarter 2026 by 11.73 % year on year. The revenue growth was below Bausch Health Companies Inc 's competitors' average revenue growth of 12.74 %, achieved in the same quarter.
Bausch Health Companies Inc , slower than the average decrease reported by the company's competitors of -43.3 %. recorded a net loss and most of the company's competitors saw a decline in earnings by -43.3 %
Bausch Health Companies Inc 's Comment on Competition and Industry Peers
The competitive landscape includes the acquisition of DURECT Corporation and the planned separation of the eye health business, which comprises Bausch + Lomb's global Vision Care, Surgical, and Pharmaceuticals businesses. Competitors identified in filings include Bausch + Lomb and DURECT Corporation.
Overall company revenue, increased less, than total company revenues, at 11.73 % and lost market share, to approximately 1.95 %. << More on BHC Market Share.
*Market share is calculated based on total revenue.
Publicly Traded Peers of Bausch Health Companies Inc
Pfizer Inc Share Performance
-1.55%
Over The Past 5 Days
Pfizer Inc
Profile
Pfizer Inc operates as a global pharmaceutical company that focuses on researching, developing, manufacturing, and marketing innovative medicines. Its business model emphasizes significant investment in research and development to build a diverse portfolio of therapies across various therapeutic areas, while leveraging strategic alliances and collaborations to enhance commercialization and drive growth.
Sarepta Therapeutics Inc's business model centers around the research, development, and commercialization of innovative genetic medicines for rare diseases, with a particular focus on Duchenne muscular dystrophy (DMD).
Third Harmonic Bio Inc's business model centers around developing and commercializing innovative therapeutic solutions through the utilization of bioinformatics and genomics.
Tiziana Life Sciences Ltd's business model focuses on the development and commercialization of innovative therapeutics in the field of immunology and oncology.
Vertex Pharmaceuticals Incs business model centers on the research and development of innovative therapies, primarily targeting cystic fibrosis and other serious diseases. They emphasize collaboration with organizations, strategic partnerships, and robust investment in R&D to deliver transformative treatments to patients and enhance their quality of life.
Sources:
Bausch Health Companies Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Bausch Health Companies Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
